Skip to main content
Equibles

BOOTHBAY FUND MANAGEMENT, LLC

Position in SPRY — ARS Pharmaceuticals, Inc.

CIK 1549230 NEW YORK, NY
Back to SPRY Full portfolio

Position in SPRY

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$12,828,047
+$10,815,754 QoQ
Shares Held
1,601,504
+539.1% QoQ
Ownership
1.61%
of shares outstanding
% of Portfolio
0.25%
of 13F equity value
Holder Rank
#16
of 209 holders
Holding Since
Dec 2022
7 quarters on record
Voting authority Sole 0% Shared 100% None 0%

Common Shares in SPRY Over Time

Shares Held

Position Value (USD)

Derivatives in SPRY

reported options exposure · as of Sep 30, 2025
CallValue
$2,056,230
CallShares
204,600
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

BOOTHBAY FUND MANAGEMENT, LLC holds $666,641,771 across 159 Biotechnology names. SPRY ranks #9 (1.9% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 RVMD
Revolution Medicines, Inc.
 465,787 $87,232,589
2 ABVX
Abivax S.A.
 563,367 $75,074,286
3 EXEL
Exelixis, Inc.
 804,095 $43,750,808
4 PCVX
Vaxcyte, Inc.
 534,163 $31,050,895
5 COGT
Cogent Biosciences, Inc.
 692,825 $26,812,327
6 CGEM
Cullinan Therapeutics, Inc.
 1,082,611 $19,714,346
7 TNGX
Tango Therapeutics, Inc.
 500,497 $15,645,536
8 AVTX
Avalo Therapeutics, Inc.
 702,051 $12,973,902

All Filings in SPRY

Export CSV
7 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $12,828,047 1,601,504
2026-03-31 $2,012,293 250,597
2025-12-31 $2,347,172 201,474
2025-09-30 $2,056,230 204,600
2025-06-30 $1,316,742 75,458
2023-03-31 $99,726 15,319
2022-12-31 $99,246 11,635